GLICLAZIDE S.R. TABLETS 30 mg - (New Product)

GLICLAZIDE S.R. TABLETS 30 mg - (New Product)
Product Description

Valpharma provides a wide range of products which includes GLICLAZIDE S.R. TABLETS 30 mg for the therapy of maturity onset Diabetes Mellitus (non-insulin-dependant or Type II), where dietary management alone has been  insufficient.Gliclazide is an oral hypoglycemic used for the control of blood glucose in people with Diabetes Mellitus (non-insulin-dependant or Type II). It is used when diet, exercise, and weight reduction have not been found to control blood glucose well enough without medication. Gliclazide increases the amount of insulin released by the pancreas and helps the body use insulin more efficiently.

  • Posology: once daily
  • Dossier: available, including bioequivalence studies vs Diamicron LM (Servier, France)
  • CPP: available
  • Registration underway: Malaysia
  • Marketing authorization granted:  Croatia, France, Spain, Syria, Tunisia, Vietnam, Jordan, Turkey
Please contact us for more information.

Read more Show less

Valpharma Group

  • Country/Region:
    Italy
  • On CPHI since:
    2015
View company profile
Categories
more categories Show less

Valpharma Group

  • Country/Region:
    Italy
  • On CPHI since:
    2015
View company profile

More Products from Valpharma Group (2)

  • DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)

    Product DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)

    Valpharma provides a wide range of products which inlcudes DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg for the treatment of hypertension, angina pectoris and some types of arrhythmia.Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the therapy and prophylaxis of coronary ins...
  • MELATONIN S.R. TABLETS 2 mg (New product)

    Product MELATONIN S.R. TABLETS 2 mg (New product)

    Valpharma provides a wide range of pharmaceutical products among which  MELATONIN S.R TABLETS 2 mg (a product under development).Melatonin S.R. tablets 2 mg is indicated as monotherapy for the short-term treatment of primary insomnia characterized by difficulty in getting to sleep and in keeping t...